In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Clinical Characterization of Brain Metastases from the Head and Neck: A Case Series

    Final Number:
    1307

    Authors:
    Corey M Gill BS, BA; Thomas F Barrett; Oscar Carrillo; Melissa Umphlett MD; Mary Fowkes MD; Richard Bakst; Brett Miles; Joshua B. Bederson MD; Priscilla Brastianos MD; Raj K Shrivastava MD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2018 Annual Meeting

    Introduction: Few case series have evaluated the clinical presentation and outcomes of patients with brain metastases from the head and neck. Identification of clinical and genomic risk factors portending reduced survival could help to guide clinical management.

    Methods: We performed a retrospective review of the Mount Sinai Electronic Health Record from 2000-2018 of patients with confirmed diagnosis of head and neck cancer and brain metastases (BM). Patients with intracranial extension of primary disease were excluded. Data related to patient demographics, diagnosis, treatment, and clinical outcomes were recorded from the medical record. Survival analysis was performed using the Kaplan-Meier method and calculated as time from BM diagnosis to date of death or last follow-up.

    Results: We identified 22 patients (16 male, 6 female) with head and neck cancer who subsequently developed a BM. Median age at BM diagnosis was 59 years (range, 41 – 81) and median time from primary diagnosis to BM was 1.7 years (range, 0.6 – 10.6). Squamous cell carcinoma (SCC) was the most common primary histologic diagnosis (n=14, 64%). Other primary diagnoses included papillary thyroid (n=3, 14%), papillary adenocarcinoma (n=1, 5%), nasopharyngeal carcinoma (n=1, 5%), mucoepidermoid carcinoma (n=1, 5%), high-grade adenocarcinoma (n=1, 5%), and adenoid cystic carcinoma (n=1, 5%). Of the 14 patients with SCC primary diagnosis, 7 (50%) were HPV positive, 5 (36%) were HPV negative, and 2 (14%) were HPV unknown status. Nine patients (41%) underwent surgical resection and radiotherapy (RT) for BM treatment, 7 patients (32%) received only RT, 2 patients (9%) received only surgical resection, and 4 patients (18%) did not receive treatment. Median overall survival from time of BM diagnosis was 4.8 months.

    Conclusions: Survival for patients with head and neck brain metastases remains dismal. SCC was the most common histologic entity to metastasize to the brain, of which 50% were HPV positive.

    Patient Care: Better understand the clinical presentation of brain metastases from the head and neck

    Learning Objectives: -To identify clinical parameters associated with head and neck BM -To evaluate clinical factors associated with survival in patients with head and neck BM -To evaluate clinical factors associated with intracranial progression in patients with head and neck BM

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy